ADAT2 and asthma: The fact that a partial downregulation of ADAT2 affects the translation of a specific subset of proteins without affecting overall protein fidelity or abundance could be used to develop new therapies designed to treat conditions caused by the accumulation of low-complexity TAPSLIVR-rich proteins, such as asthma or chronic obstructive pulmonary disease (92); or to control infection by viruses that may use MLDs for immunoevasion (93,94).